Related Experiment Videos

[Osteocalcin in children of short stature and its nocturnal variations]

M Colle1, A Ruffie, E Ruedas

  • 1Centre Aquitain d'Explorations Endocriniennes Pédiatriques, Bordeaux.

Archives Francaises De Pediatrie
|December 1, 1987
PubMed

Insights

Serum osteocalcin (Gla-P) levels are lower in young children with growth retardation. Gla-P shows nocturnal periodicity but lacks correlation with growth hormone, suggesting its potential use in evaluating short stature in children.

Area of Science:

  • Biochemistry
  • Pediatrics
  • Endocrinology

Context:

  • Growth retardation in children is a significant concern.
  • Osteocalcin (Gla-P) is a bone-specific protein reflecting bone turnover.
  • Understanding biomarkers for growth assessment is crucial.

Purpose:

  • To investigate serum osteocalcin (Gla-P) levels in children with and without growth retardation.
  • To explore the relationship between Gla-P, age, puberty, and growth hormone (hGH).
  • To assess the diurnal variation and intra-individual variability of Gla-P.

Summary:

  • Serum Gla-P was measured in children with normal stature and growth retardation, grouped by age.
  • Younger children (1-10 years) with growth retardation showed significantly lower Gla-P levels.
  • This difference diminished in older children (≥11 years). Gla-P exhibited nocturnal periodicity, peaking between 4-6 AM, but no correlation with hGH was found.
  • Significant intra-individual variations were noted over a 2-week interval.

Impact:

  • Serum osteocalcin (Gla-P) may be a useful biomarker for evaluating growth retardation in young children.
  • The findings highlight the need for standardized blood sampling protocols for Gla-P assessment in pediatric populations.
  • Further research is needed to clarify the clinical utility and variability of Gla-P in pediatric growth assessment.

Related Concept Videos